Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Afinitor(R) Phase II Data Show Positive Results For Patients With Multiple Types Of Lymphoma, Leading To Phase III Trial
New data show that Afinitor(R) (everolimus) tablets significantly shrunk tumors in 33% of patients with relapsed non-Hodgkin"s lymphoma (NHL) and Hodgkin"s disease(1). Based on results from this study and other early-stage research, Novartis has initiated a Phase III trial in the most common NHL, diffuse large B-cell lymphoma (DLBCL).
generic viagra online
Thousands Plan To Gather For The 2009 Premier School Nutrition Event In Las Vegas
When school is out, training and networking is in for the thousands of school nutrition professionals who will attend this year"s Annual National Conference of the School Nutrition Association in Las Vegas, Nevada. With the challenge of rising food and labor costs, increased demand for school meals, the legislative push for national nutrition standards through Child Nutrition Reauthorization, and the ongoing efforts to address childhood overweight, this year"s conference promises to be where the action is. Learn more about all the hot topics June 29 - July 3, 2009, in Las Vegas for SNA"s 63nd Annual National Conference (ANC.) The conference includes over 80 accredited educational breakout sessions and the largest exhibit hall in school nutrition, featuring more than 760 booths packed with healthful foods, beverages and ingredients, services, equipment and technology. ANC 2009 will be held at the Mandalay Bay in Vegas.
News of the day
Model Predicts Significant Clinical Benefits To Earlier HIV Antiviral Treatment Can Be Cost Effective In Areas Of Limited Res
Early initiation of lifesaving antiretroviral therapies should be the standard of care for all HIV-infected patients, even those in countries with limited medical and financial res, according to a study led by researchers at Massachusetts General Hospital (MGH) and the Desmond Tutu HIV Centre, University of Cape Town, South Africa.
Public Health

Prospect Therapeutics, Inc.'s GCS-100 Inhibited Blood Vessel Formation In A Variety Of Cancer Models

Joseph F. Finn, Jr., C.P.A. ("Finn"), announced today that there has been promising initial interest from pharma companies in the intellectual property of Prospect Therapeutics, Inc. ("Prospect"). In preclinical studies, GCS-100 inhibited blood vessel formation in a variety of cancer models. Development and growth of solid tumors requires new blood vessel growth, or angiogenesis, to deliver oxygen and nutrients to a tumor. Galectin-3 also plays an important role in stimulating angiogenesis in a variety of tissues. The intellectual property, regulatory dossier, fixed assets and clinical inventory will be sold at auction on Monday, June 29, 2009 at 12:00 noon. Persons interested in bidding must sign a Confidentiality Agreement ("CA") obtained from Finn"s Office - jffinnjr@earthlink.net or 781-237-8840. They will then receive a bid package. About Prospect Therapeutics, Inc. Prospect"s lead product candidate, GCS-100, is a carbohydrate molecule designed to inhibit the activity of Galectin-3, a protein found in high concentration in a broad range of human cancers and whose over-expression is associated with poor prognosis in cancer patients. Joseph F. Finn, Jr., C.P.A.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009